Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313913 | 0.90 | LMNA (0.49) | MAPTNPSR1ALDH1A1MAPK1LMNA | |
| SCHEMBL4716303 | 0.88 | MEN1 (0.51) | MAPTNPSR1ALDH1A1MAPK1LMNA | |
| SCHEMBL4716188 | 0.88 | AGTR1 (0.53) | MAPTALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL4716103 | 0.85 | MEN1 (0.51) | MAPTNPSR1ALDH1A1LMNAKMT2A | |
| SCHEMBL4713433 | 0.85 | SMN1; SMN2 (0.54) | MAPTNPSR1ALDH1A1MAPK1LMNA | |
| SCHEMBL4714806 | 0.83 | MAPT (0.54) | MAPTNPSR1ALDH1A1MAPK1LMNA | |
| SCHEMBL4716672 | 0.83 | CNR1 (0.44) | MAPTNPSR1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL4716022 | 0.82 | ALDH1A1 (0.55) | MAPTNPSR1ALDH1A1LMNAKMT2A | |
| SCHEMBL4713091 | 0.82 | ALDH1A1 (0.54) | ALDH1A1MAPK1LMNAKMT2AMEN1 | |
| SCHEMBL4716298 | 0.82 | MCOLN3 (0.54) | MAPTALDH1A1MAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | claimed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| EP-1615904-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092135-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA (SE) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | MAPT 1753/4885NPSR1 79/4885ALDH1A1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.